Report from Gambro's Annual General Meeting, March 24, 1999

Report from Gambro's Annual General Meeting, March 24, 1999 Stockholm, Sweden - Gambro AB (Stockholm Stock Exchange: GAMBaST, GAMBbST), a leading international medical technology and healthcare company, today reported the following decisions taken at the Annual General Meeting. Board of Directors Claes Dahlbäck, Gösta Gahrton, Peter H Grassmann, Juha P Kokko, Mikael Lilius, Håkan Mogren, Sven Nyman and Björn Svedberg were reelected members of the Board. At the statutory Board meeting following the Annual General Meeting, Claes Dahlbäck was elected Chairman. Berthold Lindqvist and Marcus Wallenberg had declined reelection. Dividend The Meeting approved a dividend for 1998 of SEK 1 per share, with a record date of March 29, 1999. With this record date, dividends are expected to be paid from VPC (the Swedish Securities Register Center) on April 7, 1999. Changes in the Articles of Association The proposals for amendments to the Articles of Association were approved including a change in §3 (the object clause) to better reflect Gambro's current businesses. The object of the activities is to conduct industrial business in the medical technical field and to provide healthcare services. Changes were also approved mandated by changes in the Swedish Companies Act regarding appointment of auditors for four years, details regard-ing notice of meetings of shareholders and the agenda for Annual General Meetings. For further information please contact: Bengt Modéer, Senior Vice President, Corporate Communications, tel. +46-8-613 65 00, +46-70-513 65 33 Anna Augustson, European Investor Relations Manager, tel. +46-8-613 65 35, +46-70-513 65 34 Gambro is a global medical technology and healthcare company with leading positions in renal care - services and products - and blood component technology (BCT). Gambro is the second largest provider of kidney dialysis services in the world. Gambro treats about 40,000 patients in 460 clinics worldwide. Renal care products comprise dialyzers, dialysis machines, blood lines and dialysis fluid. BCT includes products for the separation and handling of blood components. The group, with revenue of approximately SEK 19 billion (USD 2.3 billion) has approximately 18,000 employees in some 40 countries. ------------------------------------------------------------ Please visit http://www.bit.se for further information The following files are available for download: http://www.bit.se/bitonline/1999/03/24/19990324BIT00140/bit0001.doc http://www.bit.se/bitonline/1999/03/24/19990324BIT00140/bit0002.pdf